Life Science insights, April 2010 |
Topics
Clinical trials in Belgium: a state-of-play
Deloitte Belgium, on behalf of the Belgian pharmaceutical industry association (pharma.be) and in collaboration with the Belgian federal agency for medicines and health products (FAGG/AFMPS), recently published a study analysing the recent evolution of clinical trials in Belgium.
Deloitte & World Economic Forum’s Healthcare Governors’ meeting
The World Economic Forum is looking to understand the role it can play in improving the use of health data through the development of a global charter. Deloitte has been assisting the Forum to determine the viability of developing a health data charter.
What’s new in NICE’s latest STA template
In October 2009, the National Institute for Health and Clinical Excellence (NICE) in the UK released its latest Single Technology Appraisal (STA) template for manufacturer‟s/sponsor‟s evidence submission. An update of NICE‟s 2008 guidance, it brings changes to: reporting of non-randomized controlled trials, equity and equality, executive summary, budget impact and Probabilistic Sensitivity Analysis (PSA).
Shared services for hospital systems: It is your turn
Done well, the use of shared services has the potential to greatly help hospital systems in their efforts to navigate a challenging economic landscape without forcing them to compromise the quality of patient care.
Life science insights, April 2010